Study on Personalized Treatment for Advanced Non-Small Cell Lung Cancer Using Protein Markers

Sponsor: University of California, Davis

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT07250477

Provider View

This clinical trial is testing a new approach to treating advanced non-small cell lung cancer (NSCLC) by using protein markers to guide therapy choices. The study aims to see if this personalized treatment can help patients live longer without their cancer getting worse.

Patient Parameters

Program Overview

The purpose of this study is to find out if using protein markers to guide treatment decisions can improve outcomes for patients with advanced non-small cell lung cancer (NSCLC) who have not received treatment before. The study will compare this personalized approach to the standard treatment to see if it helps patients live longer without their cancer progressing over 12 months.

Description

In this study, participants will be randomly assigned to one of two groups. One group will receive a personalized treatment plan based on protein markers and other assessments, which will help doctors choose the best combination of standard treatments, including immune therapy and possibly chemotherapy. The other group will receive the standard treatment based on current medical guidelines.

The main goal is to see if the personalized treatment helps patients live longer without their cancer getting worse over a year. The study will also look at how well patients are doing overall and how their tumors respond to the treatment. Researchers hope that using protein markers to guide treatment will lead to better outcomes for patients with advanced NSCLC.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery or has spread to other parts of the body.
  • Be 18 years or older.
  • Be in relatively good health, able to carry out daily activities with some limitations.
  • Understand the study and agree to sign an informed consent form.
  • Be willing to follow all study procedures and requirements.

Exclusion Criteria

  • Have a tumor with specific genetic changes that require different treatments.
  • Have medical conditions that prevent the use of immune therapy, as determined by the doctor.
  • Have received previous treatment for advanced NSCLC, unless it was completed more than 80 days before joining the study.
  • Have any condition that the doctor believes would affect safety or ability to follow the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.